PM-NIPAV-FGF0

PepMix™ Nipah Virus (Fusion Glycoprotein F0)

US$634.00

In stock

Description

About PepMix™ Nipah Virus (Fusion Glycoprotein F0)

Pool of 134 peptides derived from a peptide scan (15mers with 11aa overlap) through Glycoprotein (Swiss-Prot ID: Q9IH63) - Protein F of Nipah virus.

PepMix™ Nipah Virus (Fusion Glycoprotein F0) - Specifications

Amount: 25 µg (approx. 15 nmol) / peptide (for stimulation of up to 2,5 x 108 cells)
Purity: Development Grade: each peptide purified to > 70% (HPLC/MS)
(equivalent to an average purity of 85%)
Delivery Format: Freeze-dried in glass vial
Application(s): T-cell immunity
Condition(s)/Topic(s): Infection, Fever, Encephalitis
Standard Delivery Time: 2-5 days

Visit our webpage for more information on Tropical Diseases and our corresponding products.

PepMix™ Peptide Pools
Protein-spanning mixtures of overlapping peptides (PepMix™) are extremely efficient for
- Antigen-specific T cell stimulation in T cell assays (e.g. in ELISpot, ICS, cell-mediated cytotoxicity or proliferation assays)
- In-vitro T cell expansion
- Dendritic cell pulsing
- Immune monitoring
- Cellular immune response profiling
- T cell epitope identification
- Standardization of T cell assays

Benefits of PepMix™
- Production ISO 9001 certified
- Each peptide quality controlled and guaranteed for identity and purity
- CoA and HPLC-MS data available
- High batch-to-batch consistency
- No false positive T cell responses by contaminating deletion peptides
- No toxic inhibition of T cell responses due to stringent purification of each peptide
- Minimization of endotoxin contamination due to low bioburden process
- ADCF policy in place
- HLA independent stimulation (with antigen spanning peptide pools)

References

References for PepMix™ Nipah Virus (Fusion Glycoprotein F0)

References
Read References with
PepMix™ Peptide Pools for Infectious Diseases
COVID-19 related PepMixes™
PepMix™ Control Pools

Application Notes
Peptide Tools to Support the Fight against COVID-19
Alem et al (2020) Full text
Developing Multi-HIV Antigen Specific T-Cells as a Component of a Cure Strategy
Lam et al. (2015) Full text
Peptide-stimulated Expansion of Virus-specific T cells For Preventative Treatment After Allogeneic Stem Cell Transplantation
Gary et al. (2015) Full text

Application Notes
Peptide Tools to Support the Fight against COVID-19
Alem et al (2020) Full text
Developing Multi-HIV Antigen Specific T-Cells as a Component of a Cure Strategy
Lam et al. (2015) Full text
Peptide-stimulated Expansion of Virus-specific T cells For Preventative Treatment After Allogeneic Stem Cell Transplantation
Gary et al. (2015) Full text

Documentation

Documentation for PepMix™ Nipah Virus (Fusion Glycoprotein F0)

Properties

Properties of PepMix™ Nipah Virus (Fusion Glycoprotein F0)

Properties Values
Amount: 25 µg (approx. 15 nmol) / peptide (for stimulation of up to 2,5 x 108 cells)
Application: T-cell immunity
Category: PepMix Peptide Pools
Condition / Topic: Encephalitis, Fever, Infection
Layout: Freeze-dried in glass vial
Organism: Nipah virus
Protein Name: Glycoprotein
Purity: Development Grade: each peptide purified to > 70% (HPLC/MS)
Quantification: Yes

Further Information to PepMix™ Nipah Virus (Fusion Glycoprotein F0)

Information Values
Sequence:
MVVILDKRCYCNLLILILMISECSVGILHYEKLSKIGLVKGVTRKYKIKSNPLTKDIVIKMIPNVSNMSQCTGSVMENYKTRLNGILTPIKGALEIYKNNTHDLVGDVRLAGVIMAGVAIGIATAAQITAGVALYEAMKNADNINKLKSSIESTNEAVVKLQETAEKTVYVLTALQDYINTNLVPTIDKISCKQTELSLDLALSKYLSDLLFVFGPNLQDPVSNSMTIQAISQAFGGNYETLLRTLGYATEDFDDLLESDSITGQIIYVDLSSYYIIVRVYFPILTEIQQAYIQELLPVSFNNDNSEWISIVPNFILVRNTLISNIEIGFCLITKRSVICNQDYATPMTNNMRECLTGSTEKCPRELVVSSHVPRFALSNGVLFANCISVTCQCQTTGRAISQSGEQTLLMIDNTTCPTAVLGNVIISLGKYLGSVNYNSEGIAIGPPVFTDKVDISSQISSMNQSLQQSKDYIKEAQRLLDTVNPSLISMLSMIILYVLSIASLCIGLITFISFIIVEKKRNTYSRLEDRRVRPTSSGDLYYIGT
Specifications: Antigen-spanning peptide pool
Loading...
TÜV Rheinland certified
Health - made in Germany
Quality Assurance

All production is ISO 9001:2015 certified.

Check our list of products, click and go.

Get a quote